Subconjunctival bevacizumab for corneal neovascularization.
OBJECTIVE
To report the efficacy of subconjunctival bevacizumab injection in patients with corneal neovascularization (NV).


METHODS
This retrospective interventional case study included two eyes of two patients with corneal NV due to aqueous-deficient dry eye with filamentary keratitis in the first case, and corneal graft failure in the second case. Patients received a subconjunctival injection of 2.5 mg (0.1 ml) bevacizumab. Morphologic changes were investigated by slit-lamp biomicroscopy and corneal photography.


RESULTS
Corneal NV was dramatically regressed a week after injection in the first case. In the second case, minor vessels were regressed while the major one did not. No infection or inflammation was observed. No relapse was seen within the follow-up of two to three months.


CONCLUSIONS
Subconjunctival injection of bevacizumab may offer an additional strategy for the treatment of corneal NV.
Erdurmus
Mesut
M
Department of Ophthalmology, Fatih University Medical School, Alparslan Turkes Cad No: 57, 06510 Emek, Ankara, Turkey. merdurmus@yahoo.com
Totan
Yuksel
Y
D000328:Adult; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003228:Conjunctiva; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007267:Injections; D008297:Male; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab